Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.36 |
| ▸ | HTR3A | P46098 | 3/20 | 0.36 |
| ▸ | SCD | O00767 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351784 | 0.81 | IL4I1 (0.44) | CHRNA7HTR3ASCDKCNH2 | |
| SCHEMBL5356264 | 0.78 | SCD (0.37) | CHRNA7HTR3ASCDKCNH2 | |
| SCHEMBL5354327 | 0.76 | NPC1 (0.57) | CHRNA7HTR3ASCD | |
| SCHEMBL7512345 | 0.75 | CHRNA7 (0.52) | CHRNA7HTR3ASCDCHRNB4CHRNA3 | |
| SCHEMBL5351339 | 0.74 | SCD (0.38) | CHRNA7HTR3ASCDKCNH2CHRM4 | |
| SCHEMBL5351147 | 0.74 | CHRNA7 (0.40) | CHRNA7HTR3AKCNH2CHRM4CHRM5 | |
| SCHEMBL2639305 | 0.73 | CHRNA7 (0.35) | CHRNA7HTR3AKCNH2CHRM4CHRM5 | |
| SCHEMBL5673020 | 0.72 | CHRNA7 (0.38) | CHRNA7HTR3AKCNH2CHRM4CHRM5 | |
| SCHEMBL3183343 | 0.71 | CHRNA7 (0.40) | CHRNA7HTR3AKCNH2CHRM4CHRM5 | |
| SCHEMBL3202084 | 0.71 | CYP1A2 (0.46) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562945-B1 | 1,4-DIAZABICYCLO(3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH AS (DK) | 2006-11-15 | — | — | EP | claimed |
| EP-1562945-A1 | 1,4-DIAZABICYCLO(3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH A/S (DK) | 2005-08-17 | — | — | EP | claimed |
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | ANIONA APS (DK) | 2004-07-01 | — | — | US | claimed |
| WO-2004043960-A1 | 1,4-DIAZABICYCLO (3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH A/S (DK) | 2004-05-27 | — | — | WO | claimed |
| US-7223753-B2 | Diazabicyclic biaryl derivatives | NEUROSEARCH A/S (DK) | 2007-05-29 | — | — | US | disclosed |
| EP-1562945-B1 | 1,4-DIAZABICYCLO(3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH AS (DK) | 2006-11-15 | — | — | EP | disclosed |
| EP-1562945-A1 | 1,4-DIAZABICYCLO(3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH A/S (DK) | 2005-08-17 | — | — | EP | disclosed |
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | ANIONA APS (DK) | 2004-07-01 | — | — | US | disclosed |
| WO-2004043960-A1 | 1,4-DIAZABICYCLO (3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH A/S (DK) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | CHRNA6, CHRNA3, CHRNA2 | CHRNA7 5/4885HTR3A 79/4885SCD 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.